Pancreatic and Gallbladder Adverse Events Associated with Tirzepatide in Obesity Management: A Scoping Review

Background

Obesity is a chronic and relapsing condition that affects all demographics and results in comorbidities, rising healthcare costs, and social challenges. Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as a promising therapy offering significant weight reduction. However, uncertainty remains regarding its pancreatic and gallbladder safety profile across different populations and evidence sources.